Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Franquesa-Garcia Francesc, Romero-Nuñez Barbara, Martin-Pinardel Ruben, De Zanet Sandro, González-López Julio José, Escobar-Barranco Jose Juan, Ruiz-Del-Tiempo María P, Boixadera Anna, Fonollosa Alex, Gómez-Benlloch Alba, Velazquez-Villoria Daniel, Fernández-Vigo José Ignacio, Garay-Aramburu Gonzaga, Parrado-Carrillo Alba, Castillon Luis, Gómez Sánchez Sandra, Lavid Francisco Javier, Arruabarrena Carolina, Figueras-Roca Marc, Bernal-Morales Carolina, Ciller Carlos, Zarranz-Ventura Javier, DIADEMA investigators
Аннотация
METHODS: This was a multicentre, real-world, national DME database and associated OCT dataset study. Demographics, visual acuity (VA), treatments and visit data were collected using a validated web-based tool (Fight Retinal Blindness). Fluid compartment quantifications, including intraretinal fluid (IRF) and subretinal fluid (SRF), were measured in nanolitres (nL) using a validated AI tool (Discovery). Univariate and multivariate regression mixed models evaluated associations between anatomical variables and VA outcomes.
RESULTS: A total of 101 treatment-naïve DME eyes were grouped into quartiles according to their fluid volume for each fluid compartment (Q1: lowest volume, Q4: highest volume). Baseline IRF was associated with greater VA gains at month 12 (+6.34 letters, p=0.07) but poorer final VA (-8.95, p=0.07), while SRF was associated with worse final VA at 12 months (-12.5, p=0.01). At month 3, IRF was associated with a VA decrease at 12 months (-13.7, p=0.02) and lower final VA (-29.8, p<0.001). At month 12, IRF was associated with lower final VA (-11.6, p=0.03). Quantitatively, a reduction of 100 nL of IRF at 3 months was associated with a +1.54 letters gain (p=0.03) in the multivariate analysis.
CONCLUSION: This real-world, multicentre study describes objective baseline fluid volumes that predict visual outcomes at 12 months in routine clinical care. Accurate quantification of baseline fluid volumes may play a predictive role for final visual outcomes.